109 related articles for article (PubMed ID: 26049107)
1. Differential binding of prohibitin-2 to estrogen receptor α and to drug-resistant ERα mutants.
Chigira T; Nagatoishi S; Tsumoto K
Biochem Biophys Res Commun; 2015 Aug; 463(4):726-31. PubMed ID: 26049107
[TBL] [Abstract][Full Text] [Related]
2. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL
Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285
[TBL] [Abstract][Full Text] [Related]
3. D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer.
Merenbakh-Lamin K; Ben-Baruch N; Yeheskel A; Dvir A; Soussan-Gutman L; Jeselsohn R; Yelensky R; Brown M; Miller VA; Sarid D; Rizel S; Klein B; Rubinek T; Wolf I
Cancer Res; 2013 Dec; 73(23):6856-64. PubMed ID: 24217577
[TBL] [Abstract][Full Text] [Related]
4. Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in
Hosfield DJ; Weber S; Li NS; Sauvage M; Joiner CF; Hancock GR; Sullivan EA; Ndukwe E; Han R; Cush S; Lainé M; Mader SC; Greene GL; Fanning SW
Elife; 2022 May; 11():. PubMed ID: 35575456
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation.
Fanning SW; Mayne CG; Dharmarajan V; Carlson KE; Martin TA; Novick SJ; Toy W; Green B; Panchamukhi S; Katzenellenbogen BS; Tajkhorshid E; Griffin PR; Shen Y; Chandarlapaty S; Katzenellenbogen JA; Greene GL
Elife; 2016 Feb; 5():. PubMed ID: 26836308
[TBL] [Abstract][Full Text] [Related]
6. Role of aspartate 351 in transactivation and active conformation of estrogen receptor alpha.
Kim JH; Lee MH; Kim BJ; Kim JH; Han SJ; Kim HY; Stallcup MR
J Mol Endocrinol; 2005 Dec; 35(3):449-64. PubMed ID: 16326832
[TBL] [Abstract][Full Text] [Related]
7. Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells.
Yoshimaru T; Komatsu M; Matsuo T; Chen YA; Murakami Y; Mizuguchi K; Mizohata E; Inoue T; Akiyama M; Yamaguchi R; Imoto S; Miyano S; Miyoshi Y; Sasa M; Nakamura Y; Katagiri T
Nat Commun; 2013; 4():2443. PubMed ID: 24051437
[TBL] [Abstract][Full Text] [Related]
8. Modulator recognition factor 1, an AT-rich interaction domain family member, is a novel corepressor for estrogen receptor alpha.
Georgescu SP; Li JH; Lu Q; Karas RH; Brown M; Mendelsohn ME
Mol Endocrinol; 2005 Oct; 19(10):2491-501. PubMed ID: 15941852
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα
Puyang X; Furman C; Zheng GZ; Wu ZJ; Banka D; Aithal K; Agoulnik S; Bolduc DM; Buonamici S; Caleb B; Das S; Eckley S; Fekkes P; Hao MH; Hart A; Houtman R; Irwin S; Joshi JJ; Karr C; Kim A; Kumar N; Kumar P; Kuznetsov G; Lai WG; Larsen N; Mackenzie C; Martin LA; Melchers D; Moriarty A; Nguyen TV; Norris J; O'Shea M; Pancholi S; Prajapati S; Rajagopalan S; Reynolds DJ; Rimkunas V; Rioux N; Ribas R; Siu A; Sivakumar S; Subramanian V; Thomas M; Vaillancourt FH; Wang J; Wardell S; Wick MJ; Yao S; Yu L; Warmuth M; Smith PG; Zhu P; Korpal M
Cancer Discov; 2018 Sep; 8(9):1176-1193. PubMed ID: 29991605
[TBL] [Abstract][Full Text] [Related]
10. A protein-fragment complementation assay reveals that celastrol and gambogic acid suppress ERα mutants in breast cancer.
Liu X; Hu Q; Wang W; Ma H; Pu J; Cui J; Gong T; Wu Y; Lu W; Huang J
Biochem Pharmacol; 2021 Jun; 188():114583. PubMed ID: 33915156
[TBL] [Abstract][Full Text] [Related]
11. Modulation of estrogen receptor alpha protein level and survival function by DBC-1.
Trauernicht AM; Kim SJ; Kim NH; Boyer TG
Mol Endocrinol; 2007 Jul; 21(7):1526-36. PubMed ID: 17473282
[TBL] [Abstract][Full Text] [Related]
12. BIG3 Inhibits the Estrogen-Dependent Nuclear Translocation of PHB2 via Multiple Karyopherin-Alpha Proteins in Breast Cancer Cells.
Kim NH; Yoshimaru T; Chen YA; Matsuo T; Komatsu M; Miyoshi Y; Tanaka E; Sasa M; Mizuguchi K; Katagiri T
PLoS One; 2015; 10(6):e0127707. PubMed ID: 26052702
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Sueta A; Tomiguchi M; Murakami K; Omoto Y; Iwase H
BMC Cancer; 2017 Nov; 17(1):786. PubMed ID: 29166868
[TBL] [Abstract][Full Text] [Related]
14. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
[TBL] [Abstract][Full Text] [Related]
15. Nuclear receptor co-regulator Krüppel-like factor 9 and prohibitin 2 expression in estrogen-induced epithelial cell proliferation in the mouse uterus.
Pabona JM; Velarde MC; Zeng Z; Simmen FA; Simmen RC
J Endocrinol; 2009 Jan; 200(1):63-73. PubMed ID: 18835980
[TBL] [Abstract][Full Text] [Related]
16. Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors.
Zhao Y; Laws MJ; Guillen VS; Ziegler Y; Min J; Sharma A; Kim SH; Chu D; Park BH; Oesterreich S; Mao C; Shapiro DJ; Nettles KW; Katzenellenbogen JA; Katzenellenbogen BS
Cancer Res; 2017 Oct; 77(20):5602-5613. PubMed ID: 28904064
[TBL] [Abstract][Full Text] [Related]
17. Decreased responsiveness of naturally occurring mutants of human estrogen receptor alpha to estrogens and antiestrogens.
Komagata S; Nakajima M; Tsuchiya Y; Katoh M; Kizu R; Kyo S; Yokoi T
J Steroid Biochem Mol Biol; 2006 Jul; 100(1-3):79-86. PubMed ID: 16713253
[TBL] [Abstract][Full Text] [Related]
18. Structural, Thermodynamic, and Kinetic Traits of Antiestrogen-Compounds Selectively Targeting the Y537S Mutant Estrogen Receptor α Transcriptional Activity in Breast Cancer Cell Lines.
Pavlin M; Gelsomino L; Barone I; Spinello A; Catalano S; Andò S; Magistrato A
Front Chem; 2019; 7():602. PubMed ID: 31552220
[TBL] [Abstract][Full Text] [Related]
19. Strategies to degrade estrogen receptor α in primary and ESR1 mutant-expressing metastatic breast cancer.
Busonero C; Leone S; Bartoloni S; Acconcia F
Mol Cell Endocrinol; 2019 Jan; 480():107-121. PubMed ID: 30389467
[TBL] [Abstract][Full Text] [Related]
20. Xanthohumol suppresses oestrogen-signalling in breast cancer through the inhibition of BIG3-PHB2 interactions.
Yoshimaru T; Komatsu M; Tashiro E; Imoto M; Osada H; Miyoshi Y; Honda J; Sasa M; Katagiri T
Sci Rep; 2014 Dec; 4():7355. PubMed ID: 25483453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]